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Summary
Background Meta-analyses of previous randomised controlled trials concluded that the smooth muscle relaxant drugs 
tamsulosin and nifedipine assisted stone passage for people managed expectantly for ureteric colic, but emphasised 
the need for high-quality trials with wide inclusion criteria. We aimed to fulfi l this need by testing eff ectiveness of 
these drugs in a standard clinical care setting.
Methods For this multicentre, randomised, placebo-controlled trial, we recruited adults (aged 18–65 years) undergoing 
expectant management for a single ureteric stone identifi ed by CT at 24 UK hospitals. Participants were randomly 
assigned by a remote randomisation system to tamsulosin 400 μg, nifedipine 30 mg, or placebo taken daily for up to 
4 weeks, using an algorithm with centre, stone size (≤5 mm or >5 mm), and stone location (upper, mid, or lower 
ureter) as minimisation covariates. Participants, clinicians, and trial personnel were masked to treatment assignment. 
The primary outcome was the proportion of participants who did not need further intervention for stone clearance 
within 4 weeks of randomisation, analysed in a modifi ed intention-to-treat population defi ned as all eligible patients 
for whom we had primary outcome data. This trial is registered with the European Clinical Trials Database, EudraCT 
number 2010-019469-26, and as an International Standard Randomised Controlled Trial, number 69423238.
Findings Between Jan 11, 2011, and Dec 20, 2013, we randomly assigned 1167 participants, 1136 (97%) of whom were 
included in the primary analysis (17 were excluded because of ineligibility and 14 participants were lost to follow-up). 
303 (80%) of 379 participants in the placebo group did not need further intervention by 4 weeks, compared with 
307 (81%) of 378 in the tamsulosin group (adjusted risk diff erence 1·3% [95% CI –5·7 to 8·3]; p=0·73) and 304 (80%) 
of 379 in the nifedipine group (0·5% [–5·6 to 6·5]; p=0·88). No diff erence was noted between active treatment and 
placebo (p=0·78), or between tamsulosin and nifedipine (p=0·77). Serious adverse events were reported in 
three participants in the nifedipine group (one had right loin pain, diarrhoea, and vomiting; one had malaise, 
headache, and chest pain; and one had severe chest pain, diffi  culty breathing, and left arm pain) and in one participant 
in the placebo group (headache, dizziness, lightheadedness, and chronic abdominal pain).
Interpretation Tamsulosin 400 μg and nifedipine 30 mg are not eff ective at decreasing the need for further treatment 
to achieve stone clearance in 4 weeks for patients with expectantly managed ureteric colic.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © Pickard et al. Open Access article distributed under the terms of CC BY.
Introduction
Ureteric colic is defi ned as episodic severe abdominal 
pain from sustained contraction of ureteric smooth 
muscle as a kidney stone passes down the ureter into 
the bladder.1 It is a common reason for people to seek 
emergency health care and was associated with 
550 000 emergency room visits in the USA in 20092 
(costing US$3 billion) and 25 000 hospital admissions 
in England in 20123 (costing £11·6 million). After 
clinical assessment and stone localisation by non-
contrast CT of the kidneys, ureters, and bladder (CT 
KUB), patients can generally be managed at home with 
analgesia with the expectation of spontaneous stone 
passage.1 The likelihood that the stone will pass within 
4 weeks ranges between 50% and 95% depending on 
stone size and location in the ureter.4 Expectantly 
managed patients who develop recurrent pain, sepsis, 
or compromised renal function need drainage if 
necessary followed by stone clearance using endoscopy 
or extracorporeal shock wave lithotripsy.5
Treatments that increase likelihood of stone passage 
would be expected to benefi t patients with ureteric colic 
because the need for an interventional procedure will be 
reduced. The smooth muscle relaxant drugs tamsulosin 
(an α-adrenoceptor antagonist) and nifedipine (a calcium 
channel stabiliser) are possible agents, their use being 
termed medical expulsive therapy (MET).6 Meta-analyses 
of data from randomised controlled trials (RCTs) report a 
statistically signifi cant benefi t for both tamsulosin and 
nifedipine over controls for the outcome of spontaneous 
stone passage7,8 with tamsulosin better than nifedipine.8 
However, the clinical usefulness of MET is uncertain 
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because of the predominance of small, single-centre, 
low-to-moderate quality trials and variability in trial 
design with diff ering inclusion criteria and outcome 
measure ment.7,8 Despite these cautions and although not 
licensed for this indication, MET is recommended by 
clinical guidance9 and is being adopted as part of routine 
expectant management.10
We now report the clinical results of the pragmatic 
randomised Spontaneous Urinary Stone Passage 
Enabled by Drugs (SUSPEND) trial, designed to 
resolve uncertainty about the benefi t of these drugs 
when used in routine care of people with expectantly 
managed ureteric colic. We sought to establish whether 
tamsulosin or nifedipine increased the likelihood of 
spontaneous stone passage measured by the absence 
of need for further intervention and, if so, which was 
the better drug.
Methods
Study design and participants
In this randomised, placebo-controlled trial, we 
recruited patients presenting to 24 UK National Health 
Service hospitals with ureteric colic. Adults aged 
18–65 years with one stone of 10 mm or less (at the 
largest dimension) in either ureter identifi ed on CT 
KUB were included. Patients who were ineligible 
included those needing immediate intervention decided 
by clinical assessment, those with sepsis, those with 
an estimated glomerular fi ltration rate of less than 
30 mL/min, and those already taking or unable to take 
an α blocker or calcium channel stabiliser. We excluded 
people older than 65 years because nifedipine dose 
titration is recommended for this age group. Full details 
of all inclusion and exclusion  criteria are available in 
our published protocol.11
Patients gave written informed consent in line with 
Good Clinical Practice and the Declaration of Helsinki. 
The trial was approved by the East of Scotland Research 
Ethics Service (reference 10/S0501/31) and the UK 
Medicines and Healthcare products Regulatory Agency 
(MHRA; reference 2010-019469-26).
Randomisation and masking
Trained site personnel (research nurses and clinicians) 
enrolled participants at each site. Participants were 
allocated in a 1:1:1 ratio to either tamsulosin, nifedipine, 
or placebo by a remote randomisation system hosted at 
the Centre for Healthcare Randomised Trials (CHaRT) 
in Aberdeen, UK, using an algorithm with centre, stone 
size (≤5 mm or >5 mm), and stone location (upper, 
mid, or lower ureter) as minimisation covariates. Each 
randomly assigned participant was given 28 capsules 
of trial medication (over-encapsulated tamsulosin or 
nifedipine, or placebo) supplied by an independent 
source (Tayside Pharmaceuticals, Ninewells Hospital, 
Dundee, UK) who had no further involvement in the 
trial, ensuring that participants, clinicians, and trial 
personnel remained unaware of the allocated group.
Research in context
Evidence before this study
In planning our trial we identifi ed two contemporary high-
quality systematic reviews that had appraised and meta-
analysed previous randomised controlled trials in this specialty. 
One was a Cochrane review that included trials of treatment 
with α blockers retrieved from the Cochrane Renal Group’s 
Specialised Register up to July 9, 2012. Meta-analysis of 32 trials 
involving 5864 participants showed that use of α blockers 
increased likelihood of stone passage compared with control, 
with a relative risk (RR) of 1·48 (95% CI 1·33–1·64). Additionally, 
from four trials involving 3486 participants, tamsulosin seemed 
to be better than nifedipine at increasing the likelihood of stone 
passage (RR 1·19, 95% CI 1·05–1·35). Overall, the included 
studies were deemed to have a high or unclear risk of bias 
around masking and a low risk of bias around outcome 
collection and reporting. The second, a systematic review by 
Seitz and colleagues, searched Medline, Embase, the Cochrane 
Central Register of Controlled Trials, and the Cochrane Database 
of Systematic Reviews up to Dec 31, 2008, for randomised trials 
of use of both α blockers and calcium channel stabilisers as 
medical expulsive therapy (MET). Combining all 29 studies 
involving 2419 participants, they noted that MET increased the 
likelihood of spontaneous stone passage (RR 1·45, 95% CI 
1·34–1·57). Additionally, they found evidence from nine trials 
involving 686 participants that nifedipine increased likelihood 
of stone passage compared with controls (RR 1·49, 95% CI 
1·33–1·66). Overall, the trials were found to be of low-to-
moderate quality on the basis of a validated scoring method.
Added value of this study
Both reviews emphasised uncertainty in estimates of eff ect due 
to the small size of most component studies, diff erences in 
inclusion criteria and outcome measurement, and inadequate 
masking of participants and assessors. We sought to overcome 
these defi ciencies by designing a large, multicentre trial with 
robust means of concealment of allocated treatment. We also 
chose a clinically relevant, attributable, and clear primary 
outcome measure. Using this method we established that 
neither the most frequently used α blocker, tamsulosin, or the 
calcium channel stabiliser nifedipine showed any clinically 
useful benefi t for increasing stone passage measured by the 
absence of need for further intervention.
Implications of all the evidence
Results of previous studies showed a positive benefi t on 
spontaneous stone passage with these agents. However, our 
methodologically sound and large trial off ers a strong evidence 
base for the alternative view that they are unlikely to be useful 
in the routine clinical care of people with ureteric colic.
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Procedures
Participants self-administered tamsulosin 400 μg, 
nifedipine 30 mg, or placebo orally once daily until 
spontaneous stone passage occurred, the need for inter-
vention was agreed, or until 4 weeks had passed since 
randomisation, whichever came fi rst. We did not verify 
adherence to trial medication.
Baseline data were collected before randomisation in 
hospital. Local research staff  obtained follow-up data by 
use of participant questionnaires, which were completed 
at home at 4 and 12 weeks, and case report forms, 
completed during clinic visits or telephone contact at 
4 and 12 weeks. No clinical tests were mandatory as part 
of the trial protocol.
Safety outcomes were reported as and when they 
happened (via the case report form, patient question-
naires, and patient and clinician report). Suspected 
serious adverse events were graded at site by the local 
principal investigator, reported to the trial offi  ce to be 
confi rmed by the chief investigator. Safety events were 
monitored by the sponsor, research ethics committee, 
and MHRA. Non-serious adverse events were not 
collected or reported.
Outcomes
The primary outcome was spontaneous stone passage in 
4 weeks, defi ned as the absence of need for additional 
interventions to assist stone passage at 4 weeks after 
randomisation. Other outcomes were pain assessed by 
participant-reported number of days of analgesic use 
and visual analogue scale at 4 weeks, time to stone 
passage assessed by the date of imaging showing no 
stone at up to 4 weeks, health status assessed by the 
Short Form (SF)-36 questionnaire, and safety assessed 
by participant report of dis continuation of medication 
due to adverse eff ects and by serious adverse events 
monitoring. We also assessed health outcomes with the 
EQ-5D questionnaire, and heath-care resource use and 
participant costs (health economic components), the 
results of which will be reported elsewhere.
Statistical analysis
The trial was powered for the most conservative 
hypothesis: that the proportion of participants who 
passed their stone would be 10% higher in the tamsulosin 
group compared with the nifedipine group (85% vs 75%). 
We prespecifi ed two comparisons, MET (tamsulosin or 
nifedipine) against placebo, and tamsulosin against 
nifedipine. We also made post-hoc comparisons of each 
agent against placebo. For 90% power and a type I error 
rate of 5%, we required 1062 participants (354 in each 
group), which we infl ated to 1200 to allow for 10% loss to 
follow-up.
We use summary statistics to describe the charac-
teristics of the trial groups at baseline and during 
follow-up. We used generalised linear models to analyse 
outcomes with adjustment for minimisation covariates, 
logistic regression for binary outcomes, and linear 
regression for continuous outcomes. We present 
treatment eff ects with 95% CI; for the primary outcome 
we present both the odds ratio and absolute risk 
diff erence. We estimated CIs for the risk diff erence 
using the delta method. We analysed data for the 
primary outcome from the modifi ed intention-to-treat 
population, which included all randomly assigned 
participants apart from those with missing primary 
outcome data and those who were found to be ineligible 
after randomisation. For secondary outcomes, we 
Figure 1: Trial profi le
Numbers of participants declining further follow-up or not responding are cumulative in direction of participant 
fl ow. CT KUB=CT of the kidneys, ureters, and bladder.
4483 screened
1998 eligible
1167 randomly assigned
8 excluded after
 randomisation
 5 out of age range
 3 prescribed 
  tamsulosin in 
  addition to allocated 
  trial medication
5 missing primary
 outcome data
391 allocated tamsulosin
378 included in primary 
 outcome
4 missing primary
 outcome data
379 included in primary 
 outcome
5 missing primary
 outcome data
379 included in primary 
 outcome
387 allocated nifedipine 389 allocated placebo
4 excluded after
 randomisation
 2 out of age range
 1 several stones
 1 no stone in ureter
5 excluded after
 randomisation
 5 out of age range
2485 not eligible
 771 stone not confirmed by CT KUB
 479 age out of range
 370 patients on contraindicated medication
 274 kidney stone only
 139 unable to comply with trial requirements
 136 several stones
 107 presence of urinary sepsis
 67 stone diameter >10 mm
 26 abnormal renal tract anatomy 
 26 bilateral stones
 25 unable or unwilling to comply with 
  contraceptive requirements
 21 no stone
 21 no stone in ureter
 10 asymptomatic
 7 pregnant or breastfeeding
 6 chronic kidney disease
 
831 not recruited
 219 unwilling to be randomised
 206 not interested in research
 199 no reason given
 195 missed by recruiters
 10 passed stone between screening and 
  randomisation
 2 other
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included participants in a complete case analysis under 
a missing-at-random assumption.
Sensitivity analyses assessed the eff ect of missing 
data on pain and health status outcomes.12 First, we 
repeated analyses using multiple imputation models 
with predictions based on all baseline covariates 
collected with results combined across ten imputed 
datasets. We then tested the robustness of these results 
using pattern mixture models, which imputed missing 
SF-36 scores across a range of potential values from 
minus half the observed SD to plus half the SD of the 
outcome being analysed.
All participants were analysed as randomised. 
Subgroup analyses explored the possible eff ect 
modifi cation of stone size, location in ureter, and sex, all 
using treatment by subgroup interaction terms and 
99% CI. Further details are available from our published 
protocol.11 We did all analyses in Stata 13. An 
accompanying cost-eff ectiveness analysis will be reported 
separately.
Role of funding source
The funder (through their peer and funding board review 
process) approved the study proposal but had no role in 
the collection, analysis, or interpretation of data, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication.
Results
Between Jan 11, 2011, and Dec 20, 2013, 1167 participants 
were randomly assigned (391 to tamsulosin, 387 to 
nifedipine, and 389 to placebo; fi gure 1). Of these, 
17 were subsequently excluded because of ineligibility 
and 14 participants were lost to follow-up, and were not 
included in the primary outcome analysis. We were able 
to ascertain the primary outcome for 1136 (97%) 
participants in the fi nal analysis. 719 (62%) of 
1150 eligible participants completed the 4-week 
questionnaire and 564 (49%) of 1150 eligible participants 
completed the 12-week questionnaire, with no 
diff erences in the proportion returned between groups 
(data not shown). Baseline characteristics were similar 
for the three groups (table 1).
Spontaneous stone passage, defi ned by absence of 
need for intervention to assist stone passage during the 
4 weeks after randomisation, did not diff er between 
groups (table 2). 307 (81%) of 378 participants in the 
tamsulosin group needed no further intervention 
compared with 304 (80%) of 379 in the nifedipine group, 
and 303 (80%) of 379 in the placebo group. These 
fi ndings were consistent across the predefi ned 
subgroups of sex, stone size, and stone location 
(fi gure 2). We also noted no diff erence in stone passage 
at up to 12 weeks (data not shown), by which time an 
additional 27 (7%) participants in the tamsulosin group, 
25 (6%) in the nifedipine group, and 28 (7%) in the 
placebo group had an intervention planned. No 
diff erences were recorded in the secondary outcomes of 
days of analgesic use (table 3), time to stone passage 
(table 3), and health status between the groups (fi gure 3). 
Tamsulosin 
(n=383)
Nifedipine 
(n=383)
Placebo (n=384)
Age, years 43·1 (11·5) 42·3 (11·0) 42·8 (12·3)
Women 68 (18%) 66 (17%) 85 (22%)
Stone size, mm 4·6 (1·6) 4·5 (1·6) 4·5 (1·7)
≤5 mm 287 (75%) 286 (75%) 286 (74%)
>5 mm 96 (25%) 97 (25%) 98 (26%)
Stone location
Upper ureter 94 (25%) 89 (23%) 93 (24%)
Middle ureter 40 (10%) 43 (11%) 44 (11%)
Lower ureter 249 (65%) 251 (66%) 247 (64%)
History of previous stone episode 130 (34%) 118 (31%) 137 (36%)
Duration of pain, days 3·0 (5·1) 2·6 (3·3) 3·2 (5·5)
Pain visual analogue score* 4·0 (3·4) 3·9 (3·4) 3·6 (3·2)
Analgesic medication before admission
Non-steroidal anti-infl ammatory drug 132 (34%) 110 (29%) 117 (30%)
Opiate 63 (16%) 67 (17%) 81 (21%)
Other 79 (21%) 86 (22%) 79 (21%)
Analgesic medication on admission
Non-steroidal anti-infl ammatory drug 279 (73%) 289 (75%) 278 (72%)
Opiate 224 (58%) 230 (60%) 230 (60%)
Other 127 (33%) 141 (37%) 133 (35%)
Antibiotic medication on admission 38 (10%) 46 (12%) 41 (11%)
SF-36 physical score† 47·0 (9·0) 46·5 (9·2) 46·1 (9·7)
SF-36 mental score† 50·2 (10·8) 50·6 (10·8) 49·6 (11·6)
Data are mean (SD) and number (%). Data do not include participants who were excluded after randomisation. 
*Ranging from 0 (no pain) to 10 (worst imaginable pain). †Ranging from 0 (maximum disability) to 100 (no 
disability).
Table 1: Baseline characteristics in eligible, randomly assigned patients
Odds ratio (95% CI); 
p value
Risk diff erence (95% CI)
MET vs placebo
Unadjusted 1·04 (0·77–1·43); 0·76 0·8% (–4·1 to 5·7)
Adjusted 1·06 (0·70–1·60); 0·78 0·9% (–5·1 to 6·8)
Tamsulosin vs nifedipine
Unadjusted 1·07 (0·74–1·53); 0·73 1·0% (–4·6 to 6·6)
Adjusted 1·06 (0·73–1·53); 0·77 0·8% (–4·5 to 6·1)
Tamsulosin vs placebo
Unadjusted 1·08 (0·76–1·56); 0·76 1·2% (–4·4 to 6·9)
Adjusted 1·09 (0·67–1·78); 0·73 1·3% (–5·7 to 8·3)
Nifedipine vs placebo
Unadjusted 1·02 (0·71–1·45); 0·93 0·2% (–5·4 to 5·9)
Adjusted 1·03 (0·68–1·56); 0·88 0·5% (–5·6 to 6·5)
MET=medical expulsive therapy.
Table 2: Primary outcome results, unadjusted and adjusted for stone 
location (lower vs middle vs upper ureter), stone size (≤5 mm vs >5 mm), 
and centre (random eff ect)
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Sensitivity analyses showed that these estimates were 
robust to assumptions about missing data for all but 
implausible scenarios (data not shown).
Serious adverse events were reported in three 
participants allocated to nifedipine (one had right loin 
pain, diarrhoea, and vomiting; one had malaise, 
headache, and chest pain; and one had severe chest pain, 
diffi  culty breathing, and left arm pain) and in one 
participant in the placebo group (headache, dizziness, 
lightheadedness, and chronic abdominal pain). No 
deaths were reported.
Discussion
The results of our trial, done in a routine care setting 
with masking of treatment allocation, showed that use 
of tamsulosin and nifedipine did not aff ect the 
proportion of patients needing further intervention to 
clear their stone during 4 weeks. This fi nding, 
suggesting similar rates of spontaneous stone passage 
across the trial groups, was consistent when possible 
modifi ers of the likelihood of spontaneous stone 
passage were taken into account, and was unchanged 
at 12 weeks after randomisation. We found no evidence 
that the drugs reduced pain, hastened time to stone 
passage, or improved health state. The precision of 
trial estimates of treatment eff ect is suffi  cient to rule 
out any clinically useful benefi t of these drugs to assist 
stone passage in this patient group at the dose and 
duration examined.
We used a pragmatic trial design in a multicentre 
setting to ensure that the drugs were tested in a manner 
aligned with present clinical practice recommendations, 
allowing direct translation of the results into standard 
clinical care. As recommended by a Cochrane review,7 the 
key entry criterion was identifi cation of one ureteric 
stone by CT KUB, ensuring that only patients with a 
symptomatic ureteric stone were included. The trial 
cohort was representative of the target population for 
MET with baseline characteristics such as stone size and 
location consistent with recent case series.13,14 We chose to 
include treatment with tamsulosin as the α-adrenoceptor 
antagonist most often used for MET, and nifedipine 
since, at the time of trial design, both agents had been 
put forward as having effi  cacy at the dose and duration 
used in our trial to increase rates of spontaneous stone 
passage.7,8 Inclusion of a placebo group, independent 
Figure 2: Subgroup analyses of the primary outcome
Interaction analyses showing odds ratio (OR) and 99% CI for the primary outcome for the subgroups of participant sex (women vs men), stone size (≤5 mm vs >5 mm), and stone location (upper vs 
middle vs lower ureter). The graphs show relation to OR of 1 (dashed line) and trial estimate of OR (solid line) for each of the comparisons of MET versus placebo, tamsulosin versus nifedipine, 
tamsulosin versus placebo, and nifedipine versus placebo. MET=medical expulsive therapy. *pinteraction value. †pinteraction value between upper ureter and lower ureter. ‡pinteraction value between middle ureter 
and lower ureter.
A MET vs placebo
Odds ratio (99% CI)
All participants
Sex
Men
Women
Size
≤5 mm
>5 mm
Location
Upper
Middle
Lower
Favours placebo Favours MET
10·5 2
B Tamsulosin vs nifedipine
Odds ratio (99% CI)
All participants
Sex
Men
Women
Size
≤5 mm
>5 mm
Location
Upper
Middle
Lower
Favours nifedipine Favours tamsulosin
10·5 2
C Tamsulosin vs placebo
Odds ratio (99% CI)
All participants
Sex
Men
Women
Size
≤5 mm
>5 mm
Location
Upper
Middle
Lower
Favours placebo Favours tamsulosin
10·5 2
D Nifedipine vs placebo
Odds ratio (99% CI)
p value p value
p value p value
All participants
Sex
Men
Women
Size
≤5 mm
>5 mm
Location
Upper
Middle
Lower
Favours placebo Favours nifedipine
10·5 2
611/757
506/625
105/132
486/569
 125/188
120/180
   61/81
430/496
303/379
239/297
  64/82
246/285
   57/94
   65/89
   36/44
 202/246
307/378
252/313
   55/65
240/284
   67/94
   62/88
   29/41
216/249
303/379
239/297
  64/82
246/285
   57/94
   65/89
   36/44
202/246
304/379
254/312
   50/67
246/285
   58/94
   58/92
   32/40
214/247
303/379
239/297
  64/82
246/285
   57/94
   65/89
   36/44
202/246
   30/378
 252/313
   55/65
240/284
    67/94
   62/88
   29/41
216/249
304/379
 254/312
   50/67
246/285
   58/94
   58/92
   32/40
 214/247
 0·85*
 0·86
 0·79
 0·23*
 0·72
 0·33
 0·12†/0·04‡
 0·29
 0·41
 0·099
 0·53*
 0·99
 0·32
 0·10*
 0·54
 0·13
 0·37†/0·01‡
 0·71
 0·23
 0·16
 0·39*
 0·78
 0·16
 0·13*
 0·54
 0·17
 0·70†/0·54‡
 0·29
 0·34
 0·97
 0·86*
 0·77
 0·62
 0·63*
 0·99
 0·88
 0·09†/0·23‡
 0·15
 0·83
 0·17
Placebo
(n/N)
MET
(n/N)
Nifedipine
(n/N)
Tamsulosin
 (n/N)
Placebo
(n/N)
Tamsulosin
(n/N)
Placebo
(n/N)
Nifedipine
 (n/N)
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control of randomisation sequence, and over-en-
capsulated trial medication supply ensured masking of 
participants, clinicians, and outcome assessors to 
allocation. We were able to collect data for the primary 
outcome for 97% of the large trial cohort, which 
surpassed the prespecifi ed sample size. The design and 
completion to target of this trial therefore allows strong 
and clinically useful conclusions to be drawn concerning 
the lack of eff ectiveness of MET.
Our trial design diff ered from other trials in two ways 
that seekers of evidence regarding the use of MET will 
have to consider. First, we chose to have wide eligibility 
criteria, including patients with symptomatic stones of 
10 mm or smaller (at the largest dimension) located at 
any site in the ureter. We chose these criteria because 
we could fi nd no evidence to suggest that use of MET is 
more eff ective if targeted at specifi c patient groups 
categorised by stone size or site. Our choice is supported 
by present guidance that recommends MET but does 
not suggest any preliminary patient categorisation,9,15 
and although data are limited, this recommendation 
seems to have led to increasing use of MET.10,16,17 Second, 
we focused on the absence of need for further 
intervention as the measure of spontaneous stone 
passage. We chose this endpoint as our primary 
outcome because it was consistent with the pragmatic 
study design assessing clinical eff ectiveness of the 
drugs. Having to undergo an intervention is a key 
outcome of interest for patients, signifying unresolved 
ill health with resultant costs. For clinicians it signifi es 
the need to upscale care, and for health-care providers it 
drives requirement for additional capacity and funding. 
Other trials designed to have a low risk of bias have 
placed an additional lower limit on stone size, typically 
3–5 mm, with or without a further restriction to patients 
with stones in the lower (distal) ureter at diagnosis.8,18 
The investigators of these trials reasoned that this 
patient group, with an expected proportion of patients 
with spontaneous passage of about 70%, were most 
likely to benefi t from MET.4 In planning our trial and 
considering the evidence, we believed that such 
subcategorisation was unwarranted and furthermore 
was unlikely to be feasible in routine emergency practice 
since it requires accurate stone measurement. Our 
study results, including the absence of any interaction 
between stone size or location and the primary outcome, 
gives us no cause to change this belief, although the 
trial was not formally powered for such subgroup 
analysis. We considered having imaging evidence of 
stone passage as a trial outcome, in common with other 
studies, but rejected it for two main reasons. Modalities 
with minimal radiation risk such as ultrasound and 
plain abdominal radiograph have inadequate diagnostic 
accuracy for the presence or absence of a stone,19 
whereas the defi nitive modality, CT KUB, has a radiation 
dose and cost that is suffi  cient to result in it not being 
recommended for this purpose by present clinical 
Tamsulosin Nifedipine Placebo Diff erence (95% CI); 
p value
Pain variables
Number of patients 247 239 231
Any self-reported use of pain 
medication in fi rst 4 weeks*
139 (56%) 133 (56%) 136 (59%)
Number of days pain medication
Mean (SD) 11·6 (8·7) 10·7 (9·0) 10·5 (8·2)
Median (IQR) 10 (4–17) 7 (4–14) 7 (4–14)
MET vs placebo† ·· ·· ·· 0·6 (–1·6 to 2·8); 0·45
Tamsulosin vs nifedipine† ·· ·· ·· 0·8 (–1·6 to 3·2); 0·50
VAS pain scale at 4 weeks
Number of patients 233 231 216
Mean score (SD) 1·0 (2·0) 1·3 (2·2) 1·2 (2·2)
MET vs placebo† ·· ·· ·· 0 (–0·4 to 0·4); 0·96
Tamsulosin vs nifedipine† ·· ·· ·· –0·3 (–0·7 to 0·1); 0·095
Time to stone passage
Number of patients 79 74 84
Mean time, days (SD) 16·5 (12·6) 16·2 (14·5) 15·9 (11·3)
Median time, days (IQR) 14 (5–27) 13 (4–26) 14 (5–25)
MET vs placebo
Unadjusted ·· ·· ·· 0·5 (–2·9 to 3·9); 0·78
Adjusted ·· ·· ·· 0·6 (–2·6 to 4·0); 0·71
Tamsulosin vs nifedipine
Unadjusted ·· ·· ·· 0·4 (–3·7 to 4·4); 0·86
Adjusted ·· ·· ·· 0·6 (–2·5 to 3·7); 0·72
All estimates adjusted for stone location (lower vs middle vs upper ureter), stone size (≤5 mm vs >5 mm), and centre 
(random eff ect). MET=medical expulsive therapy. VAS=visual analogue scale. *Percentages are derived from the 
number of responses available for each variable. †Adjusted.
Table 3: Pain variables and time to stone passage
Figure 3: Analysis of health status
SF-36 mental component scores (MCS) and SF-36 physical component scores 
(PCS) for tamsulosin, nifedipine, and placebo groups at baseline, 4 weeks, and 
12 weeks. Error bars show SD.
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guidance.19,20 In our trial population, as in routine 
clinical care, further imaging was used when clinically 
indicated by continued pain, development of infection, 
renal dysfunction, or radiographic evidence of 
obstruction on diagnosis.1 These fi ndings were the 
clinical criteria against which the need for trial 
participants to undergo further intervention was judged.
The main reason for ineligibility noted during screening 
was use of an imaging method other than CT KUB for 
stone identifi cation. The proportion of exclusions 
accounted for by this criterion fell from 43% to 25% 
during the recruitment period, suggesting an increase in 
compliance with diagnostic imaging guidance.19 Scrutiny 
of baseline characteristics gives no suggestion that 
requirement for CT KUB diagnosis resulted in systematic 
diff erences between trial groups, although overall a 
greater proportion of women were excluded by this 
criterion than were men, possibly because of radiation 
concerns. The site initiation and monitoring protocol 
used in our trial gives confi dence that the need for further 
intervention was accurately recorded by site staff  masked 
to allocation. However, some participants might have had 
persistent asymptomatic stones that did not trigger further 
intervention by 4 weeks. Such participants would be 
expected to develop symptoms by 12 weeks and at this 
timepoint a further 80 participants in our trial had 
intervention planned, but a secondary analysis including 
these events did not change our fi nding of no diff erence 
between trial groups. The proportions of patients not 
needing intervention recorded in our trial pop-
ulations—80% at 4 weeks and 73% at 12 weeks—is 
consistent with proportions reported in other cohorts.4,21 
The precision of our fi ndings related to the large sample 
size gives confi dence that the fi nding of no benefi t for 
MET was not aff ected by the overall high proportion with 
spontaneous stone passage.
Collection of measurements in our trial for participant-
reported secondary outcomes of pain control, time to 
stone passage, health status, and early discontinuation 
of trial medication, was incomplete. We found no 
evidence that the proportion of patients who completed 
measure ments diff ered between treatment groups, 
although younger people were less likely to return 
questionnaires than older people (data not shown), in 
common with previous community-based trials.22 Low 
response rates increase uncertainty around the fi nding 
of no eff ect for these secondary outcomes because of 
possible bias from missing data, but sensitivity analyses 
using imputation did not change the results. The 
amount of pain suff ered and associated disturbance to 
social and working life are important characteristics of 
the disorder, but from an eff ectiveness trial design 
perspective are diffi  cult to measure outside hospital in a 
suffi  ciently large sample for accurate estimation of any 
treatment eff ect. We also chose not to monitor 
adherence to trial medication to maintain simplicity and 
low participant burden. Despite these uncertainties we 
noted no diff erences between study groups and 
particularly no evidence of any diff erential use of 
analgesics that might act as ureteric relaxants.
The aim of this trial was to provide a precise, unbiased 
estimate of benefi t for MET in reducing need for further 
intervention to assist stone passage. We minimised 
allocation bias using a robust randomisation process 
and ascertainment bias by maintaining masking of all 
participants involved in the trial until data analysis, and 
recruited to a large target sample size with complete 
attribution of the primary outcome. These characteristics 
mean that results from our trial provide the highest 
quality evidence about clinical eff ectiveness of MET, 
since systematic reviews underpinning clinical guidance 
recommendations have all commented on the generally 
unclear risk of bias and low methodological quality of 
previous trials.7,8,23 Diff erences in inclusion criteria, trial 
design, and outcome measurement limit the opportunity 
for qualitative or meta-analytical comparison of com-
ponent trials reported in these reviews with our trial 
results. Concurrent with our trial, an alternative 
α-adrenoceptor antagonist, silodosin, has been studied 
with initial small trials suggesting benefi t.24,25 A 
subsequent multicentre trial reported that silodosin did 
not increase stone passage compared with placebo, 
although the prestated sample size was not attained, 
limiting certainty of the result.18 Seekers of evidence 
often have to decide whether to base treatment decisions 
on a meta-analysis of several small low-quality trials 
typically showing larger diff erences, or on one large 
high-quality trial with a smaller eff ect size or a fi nding 
of no eff ect.26 A recent review of this dilemma advises 
that judgments should involve careful consideration of 
qualitative and quantitative properties in each specifi c 
circumstance with further sensitivity analyses when 
possible.27 Our judgment is that the results of our trial 
provide conclusive evidence that the eff ect of both 
tamsulosin and nifedipine in increasing the likelihood 
of stone passage as measured by the need for 
intervention is close to zero. Our trial results suggest 
that these drugs, with a 30-day cost of about US$20 
(£13; €18), should not be off ered to patients with ureteric 
colic managed expectantly, giving providers of health 
care an opportunity to reallocate resources elsewhere. 
The precision of our result, ruling out any clinically 
meaningful benefi t, suggests that further trials 
involving these agents for increasing spontaneous stone 
passage rates will be futile. Additionally, subgroup 
analyses did not suggest any patient or stone 
characteristics predictive of benefi t from MET.
Ureteric colic is a common, painful disorder and 
simple treatments that would make spontaneous stone 
passage more likely and quicker are still needed. 
Although α-adrenoceptor antagonists (tamsulosin) and 
calcium channel stabilisers (nifedipine) are ineff ective, 
alternative classes of agents should continue to be 
identifi ed and trialled.28
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